Holen Sie sich die Stockscreener-App
4.1443
2.81%
-0.1257
Schlusskurs vom Vortag:
$4.27
Offen:
$4.26
24-Stunden-Volumen:
52,713
Relative Volume:
0.25
Marktkapitalisierung:
$135.64M
Einnahmen:
$1.95M
Nettoeinkommen (Verlust:
$-47.84M
KGV:
-2.7942
EPS:
-1.4832
Netto-Cashflow:
$-27.46M
1W Leistung:
+3.49%
1M Leistung:
-14.08%
6M Leistung:
-23.15%
1J Leistung:
+55.43%
1-Tages-Spanne:
$4.04
$4.26
1-Wochen-Bereich:
$3.85
$4.3213
52-Wochen-Spanne:
$2.42
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.145 | 139.73M | 1.95M | -47.84M | -27.46M | -1.4832 |
TMO
Thermo Fisher Scientific Inc
|
606.45 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
204.91 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.84 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
255.62 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
520.54 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Medicare policy boosts iMDx transplant testing frequency - scanx.trade
Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et
iMDx executives are set to meet investors in New York - Stock Titan
Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria
Insight Molecular Q2FY26 Results: Cash burn rises to $10 million - scanx.trade
Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks
Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn
Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus
Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics advances heart tr... - Pluang
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et
Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Insight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform - scanx.trade
OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire
Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade
Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com Nigeria
Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com
Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa
Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com
IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView
Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila Times
IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 55% EPS SurpriseProfit Guidance Range - vinanet.vn
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in FocusVolatility Smirk - vinanet.vn
IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView
Earnings Preview: IMDX to Report Financial Results Post-market on August 10 - Moomoo
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - The Manila Times
IMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference - marketscreener.com
iMDx to Release Second Quarter Results on August 10, 2026 - GlobeNewswire
IMDX Rises 1.09% to $4.65 as Molecular Diagnostics Play Holds Key SupportPoint of Control - vinanet.vn
IMDX Q1 2026 Earnings: Narrower Loss Beats Consensus, Shares Gain 1.09%Earnings Seasonality - vinanet.vn
Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX - TradingView
IMDX Q2'26 Earnings: revenue estimate is 437.50K USD - TradingView
IMDX|Insight Molecular Diagnostics Ord Shs|Price:4.700|Chg%:-0.040 - TradingKey
CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion - insights.citeline.com
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
1.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):